Biodesix, Inc. (BDSX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Biodesix, Inc. (BDSX) Healthcare & Pipeline Overview

Biodesix, Inc. is a data-driven diagnostic solutions company specializing in blood-based lung cancer tests and diagnostic services for biopharmaceutical companies. Their Nodify Lung Nodule Risk Assessment strategy and GeneStrat tests offer crucial insights for prognosis and treatment decisions, positioning them as a key player in the medical diagnostics landscape.

What Is the Investment Thesis for BDSX?

Biodesix operates in the growing lung cancer diagnostics market, leveraging its proprietary blood-based tests to improve patient outcomes and treatment decisions. With a gross margin of 82.1%, the company demonstrates strong pricing power and efficient operations. Key value drivers include the continued adoption of the Nodify Lung Nodule Risk Assessment strategy and the expansion of diagnostic services for biopharmaceutical companies. Upcoming catalysts include potential FDA approvals for new diagnostic tests and partnerships with leading healthcare providers. However, the company's negative profit margin of -33.3% indicates a need for improved cost management and increased revenue generation to achieve profitability.

Based on FMP financials and quantitative analysis

BDSX Key Highlights

Gross Margin of 82.1% indicates strong pricing power and efficient cost of goods sold management.

• Market Cap of $212M reflects the company's current valuation in the public market.
• Beta of 0.57 suggests lower volatility compared to the overall market, potentially appealing to risk-averse investors.
• Partnership with Bio-Rad Laboratories expands Biodesix's COVID-19 testing capabilities and market reach.
• Focus on blood-based lung cancer tests positions Biodesix in a high-growth area of medical diagnostics.

Who Are BDSX's Competitors?

BDSX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BDSX's Key Strengths?

Proprietary blood-based diagnostic tests.

• Data-driven approach to diagnostics.
• Partnerships with Bio-Rad and biopharmaceutical companies.
• Established brand in lung cancer diagnostics.

What Are BDSX's Weaknesses?

Negative profit margin.

• Limited geographic reach.
• Dependence on a few key products.
• Relatively small market capitalization.

What Could Drive BDSX Stock Higher?

Potential FDA approval for new diagnostic tests, expanding the company's product portfolio.

• Increasing adoption of the Nodify Lung Nodule Risk Assessment strategy among pulmonologists.
• Expansion of diagnostic services for biopharmaceutical companies, generating recurring revenue.

What Are the Key Risks for BDSX?

Financial-distress signal — its Altman Z-Score of -5.31 sits in the distress zone (elevated bankruptcy risk).

• Competition from established diagnostic companies and emerging players in the liquid biopsy market.
• Regulatory changes and reimbursement pressures impacting the pricing and adoption of diagnostic tests.
• Dependence on a few key products, making the company vulnerable to market shifts and technological advancements.
• Negative profit margin, requiring improved cost management and increased revenue generation to achieve profitability.

What Are the Growth Opportunities for BDSX?

• Expansion of Nodify Lung Nodule Risk Assessment: Biodesix can drive growth by increasing the adoption of its Nodify XL2 and Nodify CDT tests among pulmonologists and radiologists. The market for lung nodule risk assessment is substantial, with millions of patients undergoing CT scans annually. By demonstrating the clinical and economic value of its Nodify Lung strategy, Biodesix can capture a larger share of this market, potentially reaching a multi-million dollar revenue opportunity within the next 3-5 years.
• Development and Commercialization of Companion Diagnostics: Biodesix has the opportunity to develop and commercialize companion diagnostics that are paired with specific cancer therapies. This approach allows for personalized treatment decisions based on a patient's unique genomic profile. The market for companion diagnostics is growing rapidly, driven by the increasing use of targeted therapies and immunotherapies. Biodesix can leverage its expertise in molecular diagnostics to develop and commercialize companion diagnostics for lung cancer and other cancers, creating a significant revenue stream over the next 5-7 years.
• Strategic Partnerships with Biopharmaceutical Companies: Biodesix can expand its diagnostic and clinical research services to biopharmaceutical companies. These services include clinical trial testing, biomarker discovery, and companion diagnostic development. By forming strategic partnerships with leading pharmaceutical companies, Biodesix can secure long-term contracts and generate recurring revenue. The market for diagnostic services in the biopharmaceutical industry is estimated to be worth billions of dollars annually, offering a substantial growth opportunity for Biodesix.
• Geographic Expansion: Biodesix can expand its geographic reach beyond the United States. Lung cancer is a global health problem, and there is a significant need for improved diagnostic tools in many countries. By entering new markets, such as Europe and Asia, Biodesix can tap into a larger patient population and increase its revenue potential. This expansion could be achieved through partnerships with local distributors or by establishing direct sales operations in key markets, with a potential timeline of 3-5 years.
• Leveraging Data and Artificial Intelligence: Biodesix can leverage its data assets and artificial intelligence capabilities to develop new diagnostic tests and improve existing ones. By analyzing large datasets of patient data, Biodesix can identify novel biomarkers and develop algorithms that can predict treatment response and patient outcomes. This data-driven approach can lead to the development of more accurate and personalized diagnostic tests, giving Biodesix a competitive advantage in the market. The application of AI in diagnostics is a rapidly growing field, with the potential to revolutionize healthcare over the next decade.

What Are BDSX's Competitive Advantages?

• Proprietary blood-based diagnostic tests with established clinical utility.
• Data-driven approach to diagnostics, leveraging large datasets and artificial intelligence.
• Strategic partnerships with leading healthcare providers and biopharmaceutical companies.
• Established brand reputation and market presence in the lung cancer diagnostics space.

What Does BDSX Do?

Biodesix, Inc., founded in 2005 and headquartered in Boulder, Colorado, operates as a data-driven diagnostic solutions company within the United States. Originally incorporated as Elston Technologies, Inc., the company has evolved to focus on developing and commercializing innovative blood-based diagnostic tests, primarily in the field of lung cancer. Their core offerings include the Nodify XL2 and Nodify CDT tests, which are marketed together as part of the Nodify Lung Nodule Risk Assessment testing strategy. These tests are designed to assess the risk of lung cancer in patients with suspicious lung nodules, aiding physicians in determining the appropriate treatment pathway and reclassifying malignancy risk. In addition to nodule risk assessment, Biodesix offers GeneStrat ddPCR and VeriStrat tests, which are utilized in the diagnosis of lung cancer to measure the presence of mutations in the tumor and evaluate the patient's immune system. These tests provide valuable information for establishing patient prognosis and guiding treatment decisions. The company also provides the GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. Furthermore, through a partnership with Bio-Rad Laboratories, Inc., Biodesix offers the Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 test under the Biodesix WorkSafe testing program, and the Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting B-cell immune responses to SARS-CoV-2. Beyond diagnostic tests, Biodesix provides diagnostic and clinical research services, including clinical trial testing, to biopharmaceutical companies. The company is also involved in discovering, developing, and commercializing companion diagnostics, further solidifying its position as a comprehensive diagnostic solutions provider.

What Products and Services Does BDSX Offer?

• Develop and commercialize blood-based diagnostic tests for lung cancer.
• Offer the Nodify Lung Nodule Risk Assessment strategy to assess lung cancer risk.
• Provide GeneStrat ddPCR and VeriStrat tests for lung cancer diagnosis and prognosis.
• Offer the GeneStrat NGS test for comprehensive genomic profiling.
• Partner with Bio-Rad Laboratories to provide COVID-19 testing solutions.
• Offer diagnostic and clinical research services to biopharmaceutical companies.
• Discover, develop, and commercialize companion diagnostics.

How Does BDSX Make Money?

• Sales of blood-based diagnostic tests to hospitals, clinics, and physicians.
• Revenue from diagnostic and clinical research services provided to biopharmaceutical companies.
• Partnerships and collaborations with pharmaceutical companies for companion diagnostic development.
• Licensing of diagnostic technologies and intellectual property.

What Industry Does BDSX Operate In?

The medical diagnostics industry is experiencing rapid growth, driven by advancements in technology, increasing prevalence of chronic diseases, and a growing demand for personalized medicine. The lung cancer diagnostics market, in particular, is expected to see significant expansion due to the high mortality rate associated with the disease and the need for early and accurate detection. Biodesix operates in a competitive landscape that includes established diagnostic companies and emerging players focused on liquid biopsy and molecular diagnostics. The company's data-driven approach and focus on blood-based tests differentiate it within this market.

Who Are BDSX's Key Customers?

• Pulmonologists and radiologists who use Biodesix's tests to assess lung cancer risk.
• Oncologists who use Biodesix's tests to guide treatment decisions for lung cancer patients.
• Biopharmaceutical companies that utilize Biodesix's diagnostic and clinical research services.
• Hospitals and clinics that offer Biodesix's COVID-19 testing solutions.

Over the past six months, Biodesix, Inc. insiders filed 7 SEC Form 4 transactions — 2 sales and 5 purchases. On net that is roughly 43K shares acquired (about $1.0M) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: Biodesix, Inc.

Revenue for Biodesix, Inc. came in at $26.9M during Jun 2026, a 5.1% improvement versus the preceding quarter. The company recorded a net loss of $7.3M, with diluted EPS of $-0.71. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, BDSX averaged $-0.79 in diluted EPS.

BDSX Valuation & Market Position

With a $212M market cap, Biodesix, Inc. sits in the micro-cap segment of the market. Analyst price targets span from $26.00 to $35.00, with a consensus of $31.00. At the current price of $26.04, that implies approximately 19% upside potential. Relative to its peer group, BDSX's quantitative score of 21/100 is below the peer average of 35/100.

Key Financial Metrics

Return on assets is -33.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -20.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.82 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -22.0%, the inverse of the P/E and a quick read on earnings relative to price.

Biodesix, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -5.31 places it in the distress zone, a signal of elevated financial risk.

Biodesix, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 187.6% below estimates on average.

Wall Street analysts project Biodesix, Inc. revenue of about $112.0M for fiscal 2026, with EPS near $-2.67. The estimate reflects 6 contributing analysts.

Company Profile

Biodesix, Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Louisville, US. The company is led by CEO Scott Hutton. BDSX has traded publicly since 2020.

BDSX Financials

BDSX Latest News

BDSX Analyst Consensus

BDSX MoonshotScore

Biodesix, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources